• Molecular NameOxybutynin
  • SynonymOxibutinina [INN-Spanish]; Oxibutyninum; Oxybutinin; oxybutynin; Oxybutynin Base; Oxybutynin Chloride; Oxybutynin Hydrochloride; oxybutynin topical gel; Oxybutynine [INN-French]; Oxybutyninum [INN-Latin]; transdermal patch
  • Weight357.494
  • Drugbank_IDDB01062
  • ACS_NO5633-20-5
  • Show 3D model
  • LogP (experiment)4.683
  • LogP (predicted, AB/LogP v2.0)4.74
  • pka8.2
  • LogD (pH=7, predicted)3.46
  • Solubility (experiment)0.8 mg/ml
  • LogS (predicted, ACD/Labs)(ph=7)-3.4
  • LogSw (predicted, AB/LogsW2.0)0.18
  • Sw (mg/ml) (predicted, ACD/Labs)0.01
  • No.of HBond Donors1
  • No.of HBond Acceptors4
  • No.of Rotatable Bonds10
  • TPSA49.77
  • StatusFDA approved
  • AdministrationOral, transdermal
  • PharmacologyAn anticholinergic medication used to relieve urinary and bladder difficulties, including frequent urination and inability to control urination (urge incontinence), by decreasing muscle spasms of the bladder.
  • Absorption_value100.0
  • Absorption (description)N/A
  • Caco_2N/A
  • Bioavailability6.0
  • Protein binding92.0
  • Volume of distribution (VD)1.3 L/kg
  • Blood/Plasma Partitioning ratio (D_blood)N/A
  • MetabollsmMetabolized primarily by intestinal and hepatic CYP3A.
  • Half life12.4~13.2 h; 1.9 h (IV)
  • ExcretionN/A
  • Urinary Excretion<1
  • Clerance8.1 ml/min/kg
  • ToxicityN/A
  • LD50 (rat)LD50=1220 mg/kg
  • LD50 (mouse)N/A